259 related articles for article (PubMed ID: 34827232)
1. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
Lee CC; Hsieh CC; Ko WC
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
Fischer W; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Loftis AJ; Alabanza P; Lipansky F; Painter WP
medRxiv; 2021 Jun; ():. PubMed ID: 34159342
[TBL] [Abstract][Full Text] [Related]
4. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
6. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
7. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir in COVID-19: A Scoping Review.
Kaore S; Atal S
Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
[TBL] [Abstract][Full Text] [Related]
10. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review.
Kamal L; Ramadan A; Farraj S; Bahig L; Ezzat S
Saudi Pharm J; 2022 May; 30(5):508-518. PubMed ID: 35287313
[TBL] [Abstract][Full Text] [Related]
11. Molnupiravir: an antiviral drug against COVID-19.
Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
Singla S; Goyal S
Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India.
Sinha S; N K; Suram VK; Chary SS; Naik S; Singh VB; Jain MK; Suthar CP; Borthakur S; Sawardekar V; Sk N; Reddy N; Talluri L; Thakur P; Reddy M; Panapakam M; Vattipalli R
Cureus; 2022 Nov; 14(11):e31508. PubMed ID: 36532902
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
[TBL] [Abstract][Full Text] [Related]
15. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C
Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
[TBL] [Abstract][Full Text] [Related]
17. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
[TBL] [Abstract][Full Text] [Related]
18. Molnupiravir in COVID-19: A systematic review of literature.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
[TBL] [Abstract][Full Text] [Related]
19. Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Guan Y; Puenpatom A; Johnson MG; Zhang Y; Zhao Y; Surber J; Weinberg A; Brotons C; Kozlov R; Lopez R; Coetzee K; Santiaguel J; Du J; Williams-Diaz A; Brown M; Paschke A; De Anda C; Norquist JM
Clin Infect Dis; 2023 Nov; 77(11):1521-1530. PubMed ID: 37466374
[TBL] [Abstract][Full Text] [Related]
20. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C
Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
